A Review in Cancer Cell International discusses the molecular mechanisms of microRNA- 216a during tumor progression and paves the way to suggest it as a probable therapeutic and diagnostic target in cancer patients.
Considering the importance of identifying non-invasive markers to facilitate early tumor detection, in the present review we investigated the role of miR-216a during tumor progression. It has been reported that miR-216a has mainly a tumor suppressor function through the regulation of signaling pathways and transcription factors, which ultimately changes the cell cycle, apoptosis, and autophagy.
However, there are some challenges to use the miRNAs in tumor targeted therapy including the miRNA degradation by the cytoplasmic nucleases and the adverse influences of the selected miRNAs in normal biological cellular functions. Therefore, the side effects can be expected following the miRNA targeted therapy.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
The convergence of epigenetics and math to predict and intercept cancer cell behaviorIt is now widely understood that cancer is a disease of acquired defects in genes and gene function. An article published Feb. 9 in Science, and authored by Andrew Feinberg, M.D., of the Johns Hopkins Kimmel Cancer Center and the Institute for Basic Biomedical Sciences (IBBS) and Andre Levchenko, Sc.D., M.S., of the Yale School of Engineering and Applied Science, addresses new quantitative approaches to better define and measure these defects in gene function, known as epigenetics, and their interplay with the genetic landscape of cancer.
Lire la suite »
Oncolytic virus treatment produces promising results in patients with triple-negative breast cancerTriple-negative breast cancer accounts for approximately 15% of all breast cancer cases. Patients with this subtype typically have poorer outcomes compared to other breast cancers, suggesting the need for improved treatments. One new therapy being investigated at Moffitt Cancer Center involves oncolytic viruses, which infect and kill the cancer cells. In a new article published in Nature Medicine, the researchers, led by Hatem Soliman, M.D., share results from a phase 2 clinical trial of the oncolytic virus talimogene laherparepvec (TVEC) combined with standard chemotherapy in patients with early stage triple-negative breast cancer.
Lire la suite »
Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays - Scientific ReportsScientific Reports - Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays
Lire la suite »
Enhancing CAR-T cell functionality in a patient-specific manner - Nature Communications‘Manufacturing CAR-T cells is a streamlined and highly regulated procedure involving T-cell-expansion and activation on a standardised platform. Here, the authors show that a personalized approach, taking the phenotypic attributes of individual patients’ T cells into account, leads to more efficient CAR-T cell manufacturing and better CAR-T cell functionality.
Lire la suite »
Charlotte Crosby cries over mum's breast cancer diagnosis in show sceneFormer Geordie Shore star Charlotte Crosby sobbed as she told her pal about her mum Letitia's breast cancer diagnosis in a scene from her new BBC show, Charlotte in Sunderland
Lire la suite »
Leeds man's response after date diagnosed with terminal cancer told 'dump me'Andrew has been described as 'an angel' who stuck by 'fearless' Emily for almost five years
Lire la suite »